Gossamer Bio, Inc. (NASDAQ:GOSS)’s stock price traded down 7.8% on Tuesday . The company traded as low as $9.80 and last traded at $10.09. 1,206,528 shares traded hands during trading, an increase of 91% from the average session volume of 631,667 shares. The stock had previously closed at $10.94.
A number of equities analysts recently weighed in on the stock. Zacks Investment Research cut shares of Gossamer Bio from a “buy” rating to a “hold” rating in a research report on Tuesday, January 12th. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective (up previously from $15.00) on shares of Gossamer Bio in a research report on Thursday, December 17th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $21.00.
The stock’s fifty day moving average price is $10.44 and its two-hundred day moving average price is $10.92. The firm has a market capitalization of $766.11 million, a price-to-earnings ratio of -3.07 and a beta of 1.34. The company has a current ratio of 17.36, a quick ratio of 17.36 and a debt-to-equity ratio of 0.46.
About Gossamer Bio (NASDAQ:GOSS)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial.
Featured Story: Trade War
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.